102 results about "Proliferation activity" patented technology

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

An N-heterocycle-containing boric acid compound and a preparation method and application thereof are provided. The preparation method adopts 3-bromo-1-p-tosyl-1H-pyrrolo[2, 3-b]pyrimidine as a raw material to generate (3-((5-chloro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)boric acid by three steps of reaction. The (3-((5-chloro-4 (1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)boric acid has good inhibition effect on the proliferation activity of brain glioma, which is proven by cell experiments.

The application discloses a pyrrolobenzodiazepine-anthracene imide hybrid molecule and a preparation method and application thereof, and belongs to the technical field of chemical medicines. In order to solve the problems of few kinds of warheads of an existing antibody drug conjugate, single action mechanism and drug resistance easily generated in long-term use, a pyrrolobenzodiazepine-anthracene imide hybrid molecule shown in formula I and a preparation method and application thereof are provided. Experimental results show that the compound has strong anti-proliferation activity in various tumor cells such as ovarian cancer cells, gastric cancer cells and breast cancer cells, and an antibody drug conjugate thereof has good in-vivo and in-vitro anti-tumor activity and good safety.

The application discloses a dihydroquinazolinone-containing N-hydroxy amide compound and a preparation method and application thereof, relates to the technical field of medicinal chemistry, and utilizes the splicing principle to design and synthesize dihydroquinazolinone-containing N-hydroxy amide compounds with novel structures, and the compounds are tested in terms of HDAC6 protein affinity and anti-proliferation activity of cervical cancer cell Siha, and the results show that the compounds E1-E5 have better affinity to the HDAC6 protein, the IC 50 values are 4.1-85.4 nM, wherein the affinity of the compound E4 to the HDAC6 protein is higher than that of a positive control SAHA; and the compounds E1-E5 can better inhibit the proliferation of the cervical cancer cell Siha, the IC 50 values are 2.4-9.3 muM, wherein the activity of the compound E4 is the strongest.

The invention discloses an organoid culture medium, a kit and a method for culturing an organoid, and relates to the technical field of organoid culture. The organoid culture medium provided by the invention can improve the proliferation activity of the organoid, a relatively complete organoid form can be obtained through culture, and the cost of the culture medium is reduced. The tumor cell organoid obtained by adopting the organoid culture medium provided by the invention has a more complete tumor cell surface marker, and the cell damage is smaller.

The present application relates to the technical field of biology, and particularly relates to a mesenchymal stem cell culture medium and a preparation method and application thereof.The mesenchymal stem cell culture medium comprises a basic culture medium, fetal bovine serum, basic fibroblast growth factor, polymyxin B and deionized water.The present application can simultaneously improve the proliferation activity of mesenchymal stem cells and the secretion performance of HGF by simultaneously adding the basic fibroblast growth factor and the polymyxin B in the basic culture medium; more stem cells can be in the active proliferation and division process by limiting the content of the basic fibroblast growth factor in the mesenchymal stem cell culture medium to 5-50 ng / mL; and the secretion performance of HGF can be improved while the cell proliferation activity is maintained by limiting the content of the polymyxin B in the mesenchymal stem cell culture medium to 50-100 mu g / mL.

The invention relates to an HDAC1 inhibitor and a preparation method and application thereof. The HDAC1 inhibitor has a structure as shown in a formula (1). The compound shown in the formula (1) shows strong inhibitory activity on HDAC1 protease, and the IC50 value of the compound is basically smaller than 100 nM. Meanwhile, the compound disclosed by the invention also shows strong anti-proliferative activity for MC-38 tumor cells, and the IC50 value of the compound is basically less than 1 mu M, so that the compound disclosed by the invention is expected to be prepared into medicines for treating various HDAC1-mediated related diseases.

The invention discloses a polypeptide, a recombinant XI type humanized collagen formed by the polypeptide and application of the recombinant XI type humanized collagen. Through a large number of screening studies, it is found that a natural human XI type collagen core functional region of recombinant XI type humanized collagen with a triple helix structure can be formed in the in-vitro biosynthesis process. On the basis, the recombinant humanized polypeptide is designed and prepared on the basis of a natural XI type collagen core functional area, and the polypeptide can form a stable triple-helix structure. The recombinant XI type humanized collagen provided by the invention has good biological activities, including promotion of cell proliferation activity, promotion of cell adhesion activity and promotion of extracellular matrix generation or reconstruction, and is suitable for various medical or non-medical applications.

The invention relates to a lung fibroblast culture method, and belongs to the technical field of cell culture. Comprising the following steps: S1, organization preparation; s2, tissue treatment; s3, primary culture: the treated tissue blocks are attached to a culture dish, a culture solution is added, the culture solution is a primary culture system, and culture is performed in an incubator for several days until the culture dish is full of fibroblasts; s4, subculture: digesting the cells subjected to primary culture by adopting conventional 0.25% trypsin, then adding a culture solution which is a subculture system for subculture, and carrying out subculture to a fourth generation; and S5, cell identification. According to the invention, primary and subculture are respectively purified and amplified by virtue of a double culture system of fibroblasts, so that the purification of target cells is facilitated, the cell quality is good, a low-serum growth additive is used as a nutrient substance, the low-serum growth additive is more easily utilized by the cells, the proliferation of the cells is facilitated, and good proliferation activity and phenotypic stability are still kept when the cells are subcultured to the fourth generation; no obvious differentiation phenomenon occurs.

The invention discloses application of an LPIN1 inhibitor in preparation of drugs for treating FLT3-ITD mutant acute myelogenous leukemia, reducing tumor load of a patient with the FLT3-ITD mutant acute myelogenous leukemia, improving the survival rate of the patient with the FLT3-ITD mutant acute myelogenous leukemia and / or reducing the proliferation activity of primary cells of the patient with the FLT3-ITD mutant acute myelogenous leukemia. The LPIN1 inhibitor for inhibiting lipid metabolism related enzyme LPIN1 can significantly induce apoptosis of FLT3-ITD mutant AML cells, has limited influence on non-mutant AML cells, and has mutation specificity. More importantly, the LPIN1 inhibitor (such as propranolol) and the FLT3 inhibitor (such as quinatinib) are combined for use, so that a synergistic anti-leukemia effect can be generated, and a remarkable anti-tumor effect is shown in vitro and in a mouse transplantation tumor model, so that the LPIN1 inhibitor and the FLT3 inhibitor have a good application prospect.

This invention relates to the fields of stem cell culture and serum-free culture media, specifically to a serum-free culture medium for the proliferation of bovine muscle stem cells and its applications. The serum-free culture medium is based on a serum-free basal culture medium, to which food-derived small molecule compounds are added. Through further combination optimization, four food-derived small molecule compounds with synergistic effects have been obtained. This serum-free culture medium can significantly promote the proliferation of bovine muscle stem cells, effectively maintain cell proliferation activity, and cells passaged using this serum-free culture medium can still maintain good differentiation potential. This provides a stable, sufficient, and safe cell source for the industrial production of cultured meat, which is beneficial for the large-scale production of bovine muscle stem cells.

The application discloses the application of Huaxingdan in the preparation of a glioma drug in the technical field of biology and medicine, detects the influence of Huaxingdan on the proliferation activity of glioma cells U251, U87 and A172 by using an MTT method in vitro, finds that Huaxingdan has a significant inhibitory effect on the proliferation of glioma cells, and is time and concentration dependent. The influence of Huaxingdan on the apoptosis of glioma cells U87 is detected by using a flow cytometry, and it is found that Huaxingdan can induce the apoptosis of U87 cells, and is concentration dependent. The animal experiment shows that Huaxingdan can effectively inhibit the growth of glioma cells in vivo, and the HE staining shows that Huaxingdan has no toxicity in vivo, and can be used as a drug for preventing and treating glioma.

The invention belongs to the technical field of synthetic biology, and particularly relates to a polypeptide, a recombinant XI-type humanized collagen composed of the polypeptide and application of the recombinant XI-type humanized collagen. According to the invention, through a large number of screening researches, a core functional region of a natural human XI type collagen alpha1 (XI) chain and a natural human XI type collagen alpha2 (XI) chain of a recombinant XI type humanized collagen with a triple helix structure can be formed in an in-vitro biosynthesis process. Furthermore, the polypeptide capable of forming the recombinant XI type humanized collagen with the triple-helix structure and the recombinant XI type humanized collagen with the triple-helix structure based on the polypeptide are successfully expressed and prepared for the first time. The recombinant XI type humanized collagen provided by the invention has good biological activity, including promotion of cell proliferation activity and promotion of cell adhesion activity, and is suitable for various medical or non-medical applications.

The invention discloses a targeted protein degradation agent utilizing a ubiquitin-proteasome pathway as well as a preparation method and application of the targeted protein degradation agent, and belongs to the technical field of biological medicines. On the basis of a PROTAC (protein targeted degradation chimera) strategy and on the basis of imatinib, different Linkers are introduced to be connected with an E3 ubiquitin enzyme ligand Nutlin-3 derivative, a degradation tag is labeled on BCR-ABL cancer protein, and the degradation agent with the Bcr-Abl protein targeting capacity is constructed. A Western blot experiment shows that the targeted protein degradation agent shows a good degradation effect on the Bcr-Abl protein in K562 cells, and the compound WP shows a degradation effect on concentration dependence and time dependence of the Bcr-Abl protein. Tumor cell proliferation experiments show that the compound has certain inhibitory activity on K562 cells. Wherein when the Linker is dodecane-1, 12-diketone, the anti-proliferative activity is the best. An apoptosis experiment and a period experiment show that the targeted protein degradation agent can realize concentration-dependent promotion of cell apoptosis and retard cells in S and G1 / G0 periods.

The invention relates to the technical field of livestock breeding biology, and discloses a method for promoting porcine ovary granular cell proliferation, which comprises the following steps: adding a porcine follicular fluid exosome into a porcine ovary granular cell culture system, and acting for a certain time at an effective concentration, so as to improve the proliferation activity of granular cells. After the exosome treatment, the apoptosis rate of granular cells can be reduced, the cell survival rate can be improved, and the granular cells can be promoted to secrete steroid hormones, including the estradiol level and the expression of progesterone synthetase. Cell experiments prove that the follicular fluid exosome can effectively improve the activity of granular cells, promote the process of a cell cycle, inhibit cell apoptosis and remarkably enhance the synthesis capacity of steroid hormones such as estradiol and progesterone, and a new intervention strategy is provided for improving follicular development and reproductive performance of sows.

The invention discloses application of MBD3 as an intervention target in preparation of a neuroblastoma treatment medicine, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, a substance for reducing the expression level of the MBD3 gene or reducing the protein level of the MBD3 is applied to the development of a medicine for treating the neuroblastoma, and it is proved that interference on the expression of the MBD3 gene can induce the G0 / G1 phase cell cycle arrest of neuroblastoma cells and promote cell apoptosis, so that the in-vivo and in-vitro proliferation activity of the neuroblastoma cells is effectively inhibited; the small-molecule drug enbopiravidone can down-regulate the MBD3 protein level and significantly inhibit the growth of neuroblastoma cells. According to the invention, MBD3 is taken as a new target spot for treating neuroblastoma, a new direction is provided for overcoming the limitation of the existing therapy, a scientific basis is provided for developing a novel neuroblastoma treatment strategy based on MBD3 inhibition, and the application has important significance for improving the living quality and survival prognosis of high-risk children.

The present application belongs to the technical field of protein engineering and genetic engineering, and particularly relates to a recombinant collagen XVII and a preparation method and application thereof. Specifically, a brand new recombinant collagen is designed through screening, replacement and splicing, the nucleotide sequence of the recombinant collagen is optimized according to the codon bias of Pichia pastoris, a transmembrane peptide is introduced into the amino terminal of the sequence, a corresponding genetic engineering yeast strain is constructed, and the recombinant collagen is successfully prepared through fermentation. The amino acid sequence of the recombinant collagen has a homology of 100% with the corresponding region of natural human collagen XVII, and there is no immunogenicity risk caused by sequence difference. Meanwhile, the endotoxin content of the protein can be controlled through a purification process, so that no endotoxin residue is ensured. The recombinant collagen prepared by the above technical scheme has more excellent transdermal performance and cell proliferation activity, and has better stability, and therefore has good practical application value.

The invention belongs to the technical field of protein engineering and genetic engineering, and particularly relates to a recombinant XVII type collagen as well as a preparation method and application thereof. Specifically, brand new recombinant collagen is designed by means of screening, replacement, splicing and the like, pichia pastoris codon preference optimization is performed on a nucleotide sequence of the recombinant collagen, cell-penetrating peptide is introduced to an amino terminal of the sequence, a corresponding genetic engineering yeast strain is constructed and obtained, and the recombinant collagen is successfully prepared by fermentation. The homology of the amino acid sequence of the gene and the corresponding region of the natural human source XVII type collagen reaches 100%, and the immunogenicity risk caused by sequence difference does not exist; meanwhile, the endotoxin content of the protein can be controlled through a purification process, and no endotoxin residue is ensured. The recombinant collagen prepared by the technical scheme has more excellent transdermal performance and cell proliferation activity, and also has better stability, so that the recombinant collagen has good practical application value.

The invention discloses a PRPS2 protein inhibitor and application thereof in preparation of breast cancer treatment drugs, and relates to the field of medicinal chemistry. According to the invention, four compounds capable of being used as PRPS2 protein inhibitors are screened from an existing compound library based on an algorithm constructed based on the structural characteristics of the PRPS2 autoprotein, and the four compounds have obvious breast cancer cell anti-proliferation activity and are expected to become novel targeted therapeutic drugs for breast cancer, so that a new therapeutic strategy is provided for breast cancer patients.

The application discloses a powder back fern acid derivative containing a 1,2,3-triazole group and a preparation method and application thereof, and belongs to the field of pharmaceutical chemical industry. The powder back fern acid is used as a substrate, first reacts with propargylamine under the action of a condensing agent to obtain an intermediate N-propargyl powder back fern amide, then undergoes a click reaction with an azide compound to synthesize a series of powder back fern acid derivatives containing a 1,2,3-triazole. The powder back fern acid derivatives obtained are tested for cytotoxicity on five common cancer cell lines. The results show that most of the compounds exhibit obvious anti-proliferation activity on the five cancer cell lines, and meanwhile, some of the compounds can reach more than half of the inhibition rate on the five cancer cell lines at a concentration of 10 muM. The synthesis process is simple and fast, and the synthesis efficiency is high. The application is another effective way for synthesizing new compounds by modifying the structure of the powder back fern acid after amination. The powder back fern acid derivatives prepared by synthesis are expected to be applied in the field of antitumor drugs.

The invention relates to the technical field of drug dose screening, in particular to a method for screening the optimal dose of metformin for treating vascular dementia by using an OGD / R-SHSY5Y cell model, which comprises the following steps: constructing the OGD / R-SHSY5Y cell model to simulate the pathological state of vascular dementia; setting a control group, an OGD / R model group and a metformin treatment group with different concentrations, and additionally arranging a pathway inhibitor verification group; the cell proliferation activity is detected through a CCK8 method, the cell apoptosis rate is detected through an Annexin-V-FITC / PI double staining method, expression of apoptosis-related genes and key genes is detected through a qPCR method and a Western blot method, and the inflammatory factor level is detected through an ELISA method. By integrating multi-dimensional detection results, the optimal dosage of the metformin, which not only can significantly improve cell viability and inhibit cell apoptosis, but also can effectively regulate and control key gene expression and inflammatory factor balance, is screened out. Through multi-index collaborative detection and pathway mechanism verification, accurate screening of the optimal dose of the metformin for treating vascular dementia is realized.

The application discloses a chimeric body based on targeted degradation of GPX4 mediated by a molecular chaperone HSP90 and a preparation method and application thereof, and belongs to the technical field of biological medicines. Five chimeric bodies for targeted degradation of GPX4 are prepared by using the technology. The molecular chaperone HSP90 mediated protein targeted degradation chimeric body disclosed by the application can effectively induce degradation of GPX4, thereby triggering ferroptosis. Meanwhile, the chimeric body has obvious anti-proliferation activity on cell strains with high expression of GPX4, and has important significance for tumor targeted therapy.

The invention discloses a compound or pharmaceutically acceptable salt thereof as well as a preparation method and application thereof. The invention further discloses 22 compounds of the type and a chemical synthesis method thereof, the synthesis route is simple, operation and implementation are easy, and needed reagents are easy to purchase. The novel DIQ01 and the derivative thereof found in the invention can be specifically combined with a target protein KHSRP and inhibit the function of the target protein KHSRP, and the structure type is novel; compared with a plurality of clinical drugs, the compound shows better tumor anti-proliferation activity, and has good tumor selectivity and a wide treatment window. The compound and the pharmaceutical composition thereof can be used for preparing medicines for treating various tumors, and are preferably used for preventing or treating solid tumors such as colorectal cancer, breast cancer, lung cancer and the like and hematological malignant tumors.

The invention discloses a nutritional supplement containing coenzyme Q10 as well as a preparation method and application of the nutritional supplement. The core concept is that a novel covalent conjugate Pal-GHK-CoQ10 is constructed through a chemical means, and palmitoyl tripeptide-1 and carboxylated coenzyme Q10 modified by succinic anhydride are precisely connected by an amido bond. The design ingeniously solves the bottlenecks of asynchronous absorption, low bioavailability, insufficient synergistic effect and the like caused by large physicochemical property difference of the original components in the prior art. The preparation process covers the key steps of carboxylation of the coenzyme Q10, EDC / NHS mediated coupling, HPLC purification and the like. Pharmacological experiments prove that the conjugate is remarkably superior to a single component and a physical mixture thereof in the aspect of improving ATP generation and proliferation activity of cells, shows an excellent effect in skin barrier repair, and provides an innovative strategy for developing efficient anti-aging, repair and energy metabolism products.

The invention belongs to the technical field of synthetic biology, and particularly relates to recombinant XIII type humanized collagen and application thereof. According to the invention, a natural human XIII type collagen core functional region is obtained through a large number of screening researches. Based on the core functional area, the recombinant XIII type humanized collagen is successfully expressed and prepared for the first time. The invention relates to the field of biomedical materials, in particular to novel biomedical materials, which have good biological activity, including cell proliferation promoting activity and cell adhesion promoting activity, particularly have good proliferation promoting activity and adhesion promoting activity for skin fibroblasts and keratinocytes, and are suitable for various medical or non-medical applications, such as tissue repair / filling / compatibilization scenarios.

The invention provides a pharmaceutical preparation for repairing endometrial injury, and belongs to the technical field of biomedicine. The pharmaceutical preparation takes improved polypeptide as an active ingredient, and the amino acid sequence of the improved polypeptide is shown as SEQ ID NO.5. Experimental results show that the polypeptide can significantly promote proliferation and migration of human endometrial stromal cells, still maintains low cytotoxicity under high concentration, and shows excellent safety. Furthermore, in a rat endometrial mechanical injury model, the preparation can obviously increase the endometrial thickness, improve the Ki-67 positive cell rate, enhance the proliferation activity of endometrial cells and promote the repair of damaged tissues. Compared with the original polypeptide, the preparation disclosed by the invention shows unexpected technical effects in the aspects of repairing activity and safety, and has a good application prospect.

The application discloses a salicylaldehyde derivative and application thereof. The compound and pharmaceutically acceptable salt and ester thereof can inhibit the combination of STAT3 and phosphorylated polypeptide, and achieve the anti-tumor purpose. The salicylaldehyde derivative can be combined with the SH2 domain of target protein STAT3, and inhibit the combination of the target protein and phosphorylated polypeptide. Compound 25 shows good competitive inhibition activity. In the anti-proliferation activity of pancreatic cancer cells in vitro, the compound 25 has sub-micromolar anti-proliferation activity of pancreatic cancer cells, and can induce cancer cell apoptosis. In addition, the compound 25 can significantly inhibit the phosphorylation of STAT3 705 sites and 727 sites, can inhibit the proliferation of various tumor cells in vitro, and has low toxicity to normal cells. Therefore, the compound can be used for preparing a STAT3 inhibitor, and used for preparing a medicine for preventing and / or treating diseases related to tumors.

The present patent application discloses a method for purifying high-bioactivity and high-stability recombinant collagen XVII. The recombinant collagen XVII is constructed by splicing two segments of amino acid sequences derived from natural collagen XVII, repeating multiple times, and adding amino acids at the C-terminal end according to the amino acid sequence of natural collagen XVII. The recombinant collagen XVII has high proliferation activity for hair follicle stem cells (HSFC) and high stability. The method for purifying the recombinant collagen XVII of the present application is particularly suitable for large-scale purification production of the above-mentioned recombinant collagen XVII, and can obtain purified recombinant collagen XVII with a purity of up to 99% and meeting the requirements of raw materials for injection products.

The application provides a serum-free cell cryopreservation solution for epidermal stem cells and a preparation method and application thereof, and specifically belongs to the technical field of stem cell cryopreservation.The serum-free cell cryopreservation solution for epidermal stem cells comprises the following components in the following amounts: 0 g / L to 50 g / L raffinose, 3 g / L to 30 g / L dextran, 0% to 30% (volume percent) glycerol, 0% to 10% (volume percent) DMSO, 0% to 30% (volume percent) platelet lysate, and the balance of Ham's F-12; wherein the values of DMSO and glycerol are not both 0%. The serum-free cell cryopreservation solution can significantly improve the proliferation activity and colony formation ability of epidermal stem cells after resuscitation.